Entries |
Document | Title | Date |
20080206219 | Novel Indications for Transforming Growth Factor-Beta Regulators - Methods, compounds and compositions for the modulation of TGF-β are disclosed wherein the vascular permeability in a subject is altered. The compounds can be antagonists or agonists, and can be oligonucleotides, antisense oligonucleotides, small molecules, antibodies, and the like. Compounds that modulate TGF-β, regulate TGF-β bioavailabililty, or the configuration and context of type 1 collagen can be used for the treatment or prevention of diseases caused by vascular permeability. | 08-28-2008 |
20080206220 | 2031 Oxidoreductase - Method of identifying an anti-fungal agent which targets an essential protein or gene of a fungus comprising contacting a candidate substance with
| 08-28-2008 |
20080233096 | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels - A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels. | 09-25-2008 |
20080248016 | Novel Iaccase Enzymes and Their Uses - The present invention relates to novel laccase enzymes obtainable from the strains of the genus | 10-09-2008 |
20080248017 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 10-09-2008 |
20080254017 | Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids - The invention as disclosed herein provides pharmaneutical compositions and methods for treating, ameliorating, or preventing the symptoms of fatty acids imbalance and cell membrane dysfunction. The pharmaneutical compositions of the invention contain in an effective amount a first and a second composition, the first composition comprises an effective amount of one or more phosphatidylcholine formulations and the second composition comprises an effective amount of one or more constituents comprising essential fatty acid supplements, trace minerals, phenylbutyrate, electrolytes, methylating agents, reduced glutathione, or a combination thereof, in a suitable carrier. | 10-16-2008 |
20080260712 | Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability - A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize discs in scoliotic spines by increasing collagen crosslinks. This stability enhancement is caused by reducing the bending hysteresis and increasing the bending stiffness of scoliotic spines, by injecting non-toxic crosslinking reagents into the convex side of discs involved in the scoliotic curve. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time-release delivery system directly into or onto the target tissue. Methods and devices that use crosslinking agents for increasing the permeability of an intervertebral disc, improving fluid flux to the intervertebral disc, and increasing the biological viability of cells within the intervertebral disc are provided. | 10-23-2008 |
20080267943 | Innate Immune Receptor Directed Biocides - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 10-30-2008 |
20080274094 | Molecular Complex Comprising Arbutine, Ascorbic Acid, Oleuropeina or Its Derivatives Thereof and Related Uses In Medical Field - The present invention relates to a molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives and related uses in medical field, for example for the treatment of the skin, mucosa and serosa, for the treatment of skin aging, cutaneous hyperpigmentation and skin diseases. | 11-06-2008 |
20080279840 | Histaminase of vegetable origin for use in the treatment of allergic and septic shock and of allergic asthma - A histaminase of vegetable origin to be used in the treatment of allergic and septic shock and in allergic asthma, and the preparation of the histaminase for pharmaceutical use and the corresponding pharmaceutical compositions. | 11-13-2008 |
20080286256 | Methods and Compositions for Killing Spores - The invention provides a sporocidal composition comprising a laccase or a compound exhibiting laccase activity, a source of oxygen and a source of iodide ions. A method of killing or inactivating spores and a method of decontaminating a location, which has been exposed to spores, are also disclosed. | 11-20-2008 |
20080299103 | Well Preserved Aqueous Organic Compositions - Well-preserved aqueous topical compositions that satisfy one or more widely recognized organic certification standards. The compositions comprise a preservative system comprising an in situ hypoiodite generator; and a plant extract blend; optionally, an essential oil blend. Such compositions do not require synthetic preservatives, especially parabens. Suitable aqueous compositions may contain an oil phase, such as oil-in-water or water-in-oil emulsions. | 12-04-2008 |
20080305096 | METHOD AND COMPOSITION FOR PROVIDING CONTROLLED DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES - A method of providing controlled release of a biologically active substance within a subject's digestive system. The biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit. The soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances. The amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit. The oral dosage unit typically contains from about 1 to 15g of soluble fiber, and in some cases from about 3 to 5g of soluble fiber. The biologically active substance may contain phytonutrients that promote the subject's cardiovascular system, immune system, or weight management. | 12-11-2008 |
20080311101 | Method to Reduce Oxalate Concentration by Administration of Oxalate Oxidase Crystals - The invention relates to methods to prevent, treat, or slow the progression of a disorder associated with elevated oxalate concentration, the method comprising administering oxalate oxidase crystals, cross-linked crystals, or compositions containing those crystals to an individual. Oxalate oxidase crystals and compositions for administration to an individual are also provided, including stabilized crystals, such as cross-linked crystals of oxalate oxidase. | 12-18-2008 |
20080317727 | Method of skin treatment for rosacea using epidermal growth factor - Compositions and methods for the prevention and treatment of skin and ocular rosacea using epidermal growth factor and an acceptable carrier are disclosed. | 12-25-2008 |
20080317728 | Lowering Uric Acid to Prevent or Accelerate Recovery of Acute Renal Failure - Disclosed herein are methods of preventing acute renal failure, ARF, as well as treating and accelerating the recovery of patients experiencing ARF. The inventors believe that an elevated serum uric acid, either occurring at baseline in the patient, or being brought about post-operatively is a major factor leading to ARF. Specifically exemplified are methods that involve administering to a patient at risk of experiencing ARF a composition comprising a uric acid lowering agent. | 12-25-2008 |
20080317729 | Ammonium Salts and Ammonium Salt/Mineral Salt Clathrate Compounds for Use as Vehicle and Effective Form for Pharmaco-Medical Applications and for Use as Phase Transfer Agents for Chemical Applications - This invention relates to ammonium salts and stable storable ammonium salts and ammonium salt/mineral salt clathrate compounds (inclusion compounds, clusters) having acid dibasic anionic acid residues such as bicarbonate, to methods for producing them and to pharmaco-medical and chemical synthetic applications for said compounds. According to the invention, compounds for pharmaco-medical and chemical synthetic applications are produced which comprise the ammonium salt and ammonium salt/mineral salt clathrate compounds (inclusion compounds, clusters) having acid dibasic anionic acid residues of general formula I | 12-25-2008 |
20090004171 | COMPOUND PROFILING METHOD - The present invention provides a method for deriving an upstream or downstream component of a component necessary for phenotypic alteration of a living organism, the method comprising the steps of: specifying a pathway of interest related to the phenotypic alteration and a reference pathway different from the pathway of interest, and specifying a stimulant of interest and a reference stimulant which respectively stimulate the pathway of interest and the reference pathway; giving the stimulant of interest to the living organism to identify a collection of components of interest necessary for the phenotypic alteration; giving the reference stimulant to the living organism to identify a collection of reference components necessary for the phenotypic alteration; calculating an intersection between the collections of the components of interest and the reference components; and calculating a differential collection by subtracting the intersection from the collection of components of interest. | 01-01-2009 |
20090017002 | PREVENTION AND TREATMENT OF OXIDATIVE STRESS DISORDERS BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES - The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. | 01-15-2009 |
20090017003 | THIOSULFONATE ANTI-INFLAMMATORY AGENTS - The present invention relates to novel thiosulfonates derivatives. The present invention also provides methods for preventing, treating and/or reducing inflammation-associated diseases in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous or cutaneous systems as well as infective and tumoral diseases employing said compounds. | 01-15-2009 |
20090022703 | Lysyl oxidase-like 1 (LOXL1) and elastogenesis - Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers. | 01-22-2009 |
20090022704 | METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT - The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome. | 01-22-2009 |
20090028841 | OXYGEN SCAVENGING COMPOSITION, COATING COMPOSITION AND PACKAGE CONTAINING FREE FATTY ACID - An oxygen scavenging composition being an oxidizable ascorbic acid derivative, a multi-copper oxidase enzyme, and a free fatty acid wherein the enzyme is disposed upon the surface of the oxidizable ascorbic acid derivative, and wherein the free fatty acid is intermixed with the oxidizable ascorbic acid derivative. The invention extends to a coating composition thereof and a package or container containing the oxygen scavenging composition. | 01-29-2009 |
20090047267 | Process for the Preparation of A Non-Corrosive Base Solution And Methods Of Using Same - The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, Lesch-Nyhan syndrome, hemochromatosis, Alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, Parkinson's, Reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, Hepatitis C, methicillin-resistant | 02-19-2009 |
20090060894 | Treatment to aid in the metabolism of alcohol - Alcohol intoxication is a serious problem. Many individuals are more sensitive to alcohol intoxication and placed at a decided disadvantage in social drinking situations. What is proposed is a way to facilitate alcohol metabolism in individuals who have consumed alcohol by the administration of enzymes to speed the alcohols metabolism. | 03-05-2009 |
20090074740 | Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT) - A method of determining a potential of a nondiabetic or diabetic patient to benefit from reverse cholesterol transport therapy for treatment of a vascular complication, followed by methods and compositions of treating the diagnosed vascular complications comprising determining a haptoglobin phenotype of the patient. Reverse cholesterol transport therapy includes inhibition of cholesteryl ester transport protein, such as by using the compound torcetrapib. | 03-19-2009 |
20090081181 | ISOLATION OF GROWTH AND DIFFERENTIATING FACTORS FROM COLOSTRUM - The present invention concerns a novel process for isolating growth and differentiating factors present in colostrum, all in a natural way. This process is characterized by maturation steps (controlled mild acid hydrolysis) and physical steps (molecular filtration) which optimize recovery of measured growth factors and their ability to entice a response on human cells. Advantageously, this process allows the derivation and isolation of growth and differentiating factors with highly disparate sizes (or molecule weights) in pools. These pools can be used in select and varied ways, including cosmetic, cosmeceutical, nutraceutical, dermatological, pharmaceutical, medical and veterinary applications. It can also be used as a replacement to fetal calf serum to promote cell proliferation, and above all, cell differentiation. | 03-26-2009 |
20090098099 | PLANT TRANSFORMED WITH POLYNUCLEOTIDE ENCODING LEPIDOPTERAN-ACTIVE BACILLUS THURINGIENSIS DELTA-ENDOTOXIN - Disclosed are | 04-16-2009 |
20090104172 | METHODS FOR KILLING SPORES AND DISINFECTING OR STERILIZING DEVICES - The present invention provides a method for killing or inactivating spores, by contacting the spores with a haloperoxidase, hydrogen peroxide, chloride or bromide ions, and ammonium ions. | 04-23-2009 |
20090123446 | Use of IL-1 Antagonists to Treat Gout - Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited. | 05-14-2009 |
20090123447 | COMPOSITIONS AND METHODS TO INHIBIT RNA VIRAL REPRODUCTION - This invention provides methods and compositions for inhibiting replication of the genome of an RNA virus in a host cell by contacting the host cell with an effective amount of an agent that produces a subtoxic concentration of hydrogen peroxide, thereby inhibiting viral replication in the host cell. Also provided are methods and compositions for inhibiting replication of the genome of an RNA virus in a subject in need thereof by administering an effective amount of an agent that produces a subtoxic concentration of hydrogen peroxide in the subject, thereby inhibiting replication. The agents can generate hydrogen peroxide or enhance endogenous levels of hydrogen peroxide. The agents are effective against HCV independent of genotype. | 05-14-2009 |
20090175840 | INSULIN FORMULATIONS FOR INSULIN RELEASE AS A FUNCTION OF TISSUE GLUCOSE LEVELS - Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patient's tissue glucose level, which in turn maintains the patient's blood glucose level within an optimum range. The formulation is often referred to as a “smart” formulation since it modifies its release rate of insulin according to the patient's needs at a particular time. In a preferred embodiment, the formulation is designed to release insulin into the systemic circulation over time with a basal release profile following injection in a patient. In another embodiment, the formulation is designed to release insulin into the systemic circulation over time with a non-basal release profile following injection in a patient, such as a regular human insulin release profile or a prandial release profile. | 07-09-2009 |
20090196863 | METHOD OF ANTIOXIDATION AND ANTIOXIDANT-FUNCTIONING WATER - A method of antioxidation and antioxidant-functioning water that can transform an antioxidation subject that is in an oxidation state due to a deficiency of electrons, or for which protection from oxidation is desired, into a reduced state where electrons are satisfied, by promoting the breaking reaction of molecular hydrogen that is used as a substrate included in hydrogen-dissolved water into a product of active hydrogen through a process employing a catalyst on the hydrogen-dissolved water, while anticipating high benchmarks of safety on the human body and reduced environmental burden. | 08-06-2009 |
20090202509 | METHODS AND AGENTS FOR REDUCING OXIDATIVE STRESS - The present invention relates to novel methods for enhancing endogenous protection mechanisms against oxidative stress, and agents for use in such methods. In particular, the present invention provides a pharmaceutical composition which provides an oxidative signal upon administration to a subject, the signal triggering a therapeutic or prophylactic effect by priming the subject's body to combat the effects of oxidative stress. | 08-13-2009 |
20090208475 | MINA53 ASSAYS - The present invention comprises a method for assaying oxygenase activity the method comprising monitoring oxygenase activity of Mina53. | 08-20-2009 |
20090208476 | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins - The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis. | 08-20-2009 |
20090208477 | Production of high mannose proteins in plant culture - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 08-20-2009 |
20090214506 | Use of TFPI to Treat Severe Bacterial Infections - Methods for prophylactically or therapeutically treating a patient at risk of developing or diagnosed as having a severe bacterial infection involving administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog at low doses to avoid adverse side effects. | 08-27-2009 |
20090257998 | METHOD FOR TREATING HEART ATTACKS, STROKES AND DIABETIC CRISIS BY UTILIZING MODIFIED VIRUS VIRIONS TO INSERT NECESSARY PROTEIN MOLECULES AND VITAL NUTRIENTS INTO TARGETED CELLS - The common link between incurring a heart attack, suffering a stroke or diabetic crisis is related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration to produce energy molecules. Utilizing a medical treatment method comprised of a modified form of virus to deliver to cells in the body the protein molecules and nutrients needed to enhance the processes of glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation and anaerobic respiration will save lives. Providing an alternative means for brain cells and heart muscle cells to have access to proteins, nutrients such as glucose and oxygen, and energy molecules by providing these tissues with viruses that carry these vital elements to these tissues will greatly improve the survivability of individuals experiencing a heart attack, a stroke or a diabetic crisis. | 10-15-2009 |
20090257999 | Method of preventing contrast-induced nephropathy - The present invention relates to methods of preventing contrast-induced nephropathy including the step of administering an effective amount of a compound (e.g., a peroxynitrite decomposition agent, a PARP inhibitor or a superoxide dismutase mimic) to a subject to be administered a contrast agent. | 10-15-2009 |
20090263367 | COMPOSITION AND METHOD FOR PROMOTING INTERNAL HEALTH AND EXTERNAL APPEARANCE - The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and/or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect the composition of the present invention further comprises carboxy alkyl ester. The present invention also relates to a method of promoting internal health and external appearance in a subject in need, said method comprising administering to the subject a composition that promotes DNA repair, reduces body fat levels and increases lean body mass and that decreases wrinkle appearance and/or improvement in skin surface. | 10-22-2009 |
20090269324 | ANTIMICROBIAL PERACID COMPOSITIONS WITH SELECTED CATALASE ENZYMES AND METHODS OF USE IN ASEPTIC PACKAGING - The present invention relates to specially selected catalase enzymes and their use in reducing hydrogen peroxide in applications, and particularly in aseptic packaging applications. | 10-29-2009 |
20090280100 | Preventive or Therapeutic Agent for Inflammatory Ocular-Surface Diseases - [Problems] The present invention aims to provide a preventive or therapeutic agent for inflammatory ocular-surface diseases. | 11-12-2009 |
20090280101 | Method for conversion of uric acid to allantoin and related enzymes - It is described a polypeptide molecule able to selectively modulate uric acid conversion into S(+)-allantoin. A pharmaceutical composition for treating uric acid related disorders and a process to selectively modulate uric acid conversion into S(+)-allantoin are also disclosed. | 11-12-2009 |
20090280102 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF - Methods and compositions are provided for inhibiting the growth of susceptible microorganisms by contacting the microorganisms, in the presence of a peroxide and chloride or bromide, with myeloperoxidase and at least two activity enhancing agent amino acids. | 11-12-2009 |
20090291070 | Biologically Active Silver-Coated Proteins - Silver-coated proteins, being dissolvable or suspendable in aqueous media and/or retaining a biological activity of the protein and a process for preparing same are disclosed. Further disclosed are modified proteins which have a reducing moiety attached to the surface thereof and a process for preparing same. The modified proteins can be utilized for obtaining the silver-coated proteins. Further disclosed are a pharmaceutical composition containing and a method of treating bacterial and fungal infections utilizing biologically active silver-coated hydrogen peroxide producing enzymes such as glucose oxidase. Further disclosed are conductive elements that comprise the silver-coated proteins disclosed herein and electronic circuits containing same. Further disclosed are electrodes having the silver-coated proteins deposited thereon and biosensor systems utilizing same for determining a level of an analyte in a liquid sample. | 11-26-2009 |
20090297494 | Diagnostic and treatment of a mental disorder - The present invention generally relates to the field of neurological, physiological and psychotic dysfunctions associated with a mental disorder such as schizophrenia, or a predisposition therefor. The invention further relates to genes and proteins, which, when varied in their normal expression, their nucleic acid sequence or in their activity, are associated with the mental disorder. Accordingly, the present invention relates to methods for diagnosis and to methods for prevention and/or treatment of a mental disorder. The present invention additionally relates to compositions for use in diagnosis and to kits for diagnosis of a mental disorder. The invention also relates to the use of a protein or polynucleotide for the manufacture of a medicament for use in the treatment and/or prevention and to a pharmaceutical composition for use in prevention and/or treatment of a mental disorder. Further, the invention relates to methods for screening for a modulator of a mental disorder. More particularly, the present invention relates to methods, compositions and kits, a microarray and reagents for determining the presence of at least one polymorphism and/or at least one combination of polymorphisms of at least one copy of a gene involved in regulating the intracellular glutathione (GSH) level and/or GSH-oxidative stress-related gene expression in a human being. Further, the invention relates to a pharmaceutical composition for use in the treatment and/or prevention of a mental disorder, to the use of an active ingredient such as a protein or polynucleotide for the manufacture of a medicament for use in the treatment and/or prevention of a mental disorder in patients with specific polymorphisms in genes involved in regulating the intracellular GSH level and/or GSH-oxidative stress-related gene expression. The invention also relates to methods of preventing and/or treating a mental disorder comprising administering a medicament to patients having said polymorphisms and to methods of screening for a modulator of a mental disorder. | 12-03-2009 |
20090311230 | SYNTHETIC CATALYTIC FREE RADICAL SCAVENGERS USEFUL AS ANTIOXIDANTS FOR PREVENTION AND THERAPY OF DISEASE - The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds. | 12-17-2009 |
20090311231 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 12-17-2009 |
20100003232 | INSULIN-DEGRADING ENZYME MUTANTS AND METHODS OF USE - Disclosed are mutant polypeptides of insulin degrading enzymes having at least 95% amino acid identity to SEQ ID NO: 1, having at least one mutation in a region corresponding to human IDE-N or human IDE-C, having increased activity, polynucleotides encoding the polypeptides, and methods of use. | 01-07-2010 |
20100015120 | HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN - A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G | 01-21-2010 |
20100015121 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY - Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase. | 01-21-2010 |
20100028320 | Methods and Compositions for Inhibiting Diseases of the Central Nervous System - Methods and compositions for treating central nervous system diseases and disorders are disclosed. | 02-04-2010 |
20100040593 | FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY - Improved methods and compositions for the treatment of native tissues with crosslinkers are provided. The methods and compositions will find particular use in increasing resistance to tearing, fissuring, rupturing, and/or delamination. | 02-18-2010 |
20100080787 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN ENZYME WHICH IS INSOLUBLE IN AN AQUEOUS MEDIUM AS WELL AS ITS USES - The invention relates to a cosmetic or dermopharmaceutical composition, as well as these uses. | 04-01-2010 |
20100092448 | LOCAL CONTROL OF INFLAMMATION - A medical device includes a carrier and an agent. The agent is formulated to control inflammation of biological tissue, such as heart tissue, and is releasably coupled to the carrier. The carrier is configured to be disposed in operative proximity to the biological tissue to be treated by the agent. In one embodiment, the carrier is configured to release the agent or otherwise deliver the agent to the biological tissue, thus controlling inflammation of the tissue. Also, a method to improve healing of biological tissue includes placing a medical device proximate to the heart of a patient, where the medical device has a carrier and an agent configured to control inflammation, the agent is releasably coupled to the carrier. In one embodiment, the method includes causing the agent to be released from the carrier. | 04-15-2010 |
20100098679 | PROMOTION OF PEROXISOMAL CATALASE FUNCTION IN CELLS - The molecular mechanisms of peroxisome biogenesis have begun to emerge; in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor, Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H | 04-22-2010 |
20100104548 | MODULATION OF AMINO ACID METABOLISM IN THE HYPOTHALAMUS - Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal. | 04-29-2010 |
20100111921 | Use of IL-1 Antagonists to Treat Gout - Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited. | 05-06-2010 |
20100111922 | Animal model and use of 17beta-hydroxysteroid dehydrogenase type 7 in the diagnosis of anencephaly - The present invention features a non-human animal in which is deficient in the expression of endogenous 17β Hydroxysteroid Dehydrogenases Type 7 and use of the same in screening methods for agents that prevent or treat anencephaly. The present invention also provides a method for diagnosing and treating. | 05-06-2010 |
20100119500 | METHOD FOR PREPARING SILICA COMPOSITIONS, SILICA COMPOSITIONS AND USES THEREOF - A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22 G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions. | 05-13-2010 |
20100135979 | STABILIZED SUSPENSION - A stabilized, colloidal free radical reduced aqueous suspension containing a complex of amorphous Hyaluronic acid (HA) with a mean molecular weight (mean MW) in the range of 80 to 400 kDa and amorphous protein drug, such as insulin, glucagon-like peptide 1 (GLP1), human growth hormone (hGH), erythropoietin (EPO) and super oxide dismutase (SOD), and an excess amount of HA, for example a HA with a mean MW of 6-15 kDa, to minimize the water-content, is described. The composition may additionally comprise HA with a mean MW in the range between 1 and 8 kDa when it is in lyophilized free-flowing powder form. Further, a pharmaceutical composition comprising the suspension and a method of producing the suspension including production of amorphous hyaluronic acid and amorphous protein, are disclosed. The pharmaceutical composition is intended for oral as well as parenteral administration. | 06-03-2010 |
20100150897 | COMPOSITIONS AND METHODS FOR ENZYMATIC TREATMENT OF LUNG DISORDERS - A therapeutic composition for the treatment of lung diseases or disorders and diseases or disorders of the airway passages including pneumonia, acute respiratory failure, and acute respiratory distress syndrome is based on the generation of a biocidal anion by an enzymatic reaction catalyzed by a peroxidase. The peroxide utilized by the peroxidase enzyme can be endogenous or can be generated by the action of an oxidase enzyme on a suitable substrate. | 06-17-2010 |
20100158887 | DIRECT APPLICATION OF NON-TOXIC CROSSLINKING REAGENTS TO RESIST PROGRESSIVE SPINAL DEGENERATION AND DEFORMITY - A method of treatment of native, non-denatured tissue to increase resistance to tearing, fissuring, rupturing, and/or delamination, comprising the step of: contacting at least a portion of the tissue with an effective amount of a reagent that increases crosslinks in the tissue. | 06-24-2010 |
20100166723 | GENES ENCODING NEMATODE TOXINS - Compositions and methods for conferring nematicidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions including a coding sequence for nematicidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated nematicidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules including nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:4, 5, 8, 9, 13, 14, 47, 48, or 49, the nucleotide sequence set forth in SEQ ID NO:1, 2, 3, 6, 7, 10, 11, 12, 15, 45, or 46, as well as variants and fragments thereof. | 07-01-2010 |
20100166724 | USES OF THIOREDOXIN - The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth. | 07-01-2010 |
20100178282 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES - The invention is in general directed to compounds and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, methods of screening for compounds useful in preventing or alleviating the symptoms of amyloid-associated diseases, methods of diagnostic imaging of A-beta fibrils, and compounds and methods useful for studying normal or disease-associated cellular mechanisms relating to amyloid proteins. | 07-15-2010 |
20100183578 | NITROPROTEIN BIOMARKERS FOR COPD - Specific nitroprotein biomarkers may be used as prognostic and diagnostic tools for COPD. Identification of certain specific nitroprotein biomarkers allows the development of targeted therapies aimed at prevention and treatment of COPD. | 07-22-2010 |
20100189705 | BIOLOGICAL DECONTAMINATION SYSTEM - A composition for decontaminating biological pathogens and a system and method for mixing and applying the composition to contaminated sites are presented. The composition of the invention is suitable for the decontamination of biological warfare agents, including | 07-29-2010 |
20100189706 | ENZYMES FOR THE TREATMENT OF LIGNOCELLULOSICS, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides polypeptides having a lignocellulolytic activity, e.g., a glycosyl hydrolase, a cellulase, an endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a xylosidase (e.g., a β-xylosidase), an arabinofuranosidase, and/or a glucose oxidase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides that can enzymatically process (hydrolyze) sugarcane bagasse, i.e., for sugarcane bagasse degradation, or for biomass processing, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one embodiment, the invention provides thermostable and thermotolerant forms of polypeptides of the invention. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts; for example, the invention provides a multi-enzyme system that can hydrolyze polysaccharides in a bagasse component of sugarcane processed in sugar mills. The invention provides enzymes for the bioconversion of lignocellulosic residues into fermentable sugars; and these sugars can be used as a chemical feedstock for the production of ethanol and fuels, including biofuels such as bioethanol, biopropanol, biobutanol and biodiesels. | 07-29-2010 |
20100196343 | COMPOSITIONS, METHODS, DEVICES, AND SYSTEMS FOR SKIN CARE - Accordingly, a need has arisen for improved compositions, methods, devices, and systems for skin care including, without limitation, topical compositions and phototherapy devices and methods. A skin care method may comprise, in some embodiments, contacting at least a portion of the skin of a subject with a homogeneous, stable, self-foaming composition, illuminating the at least a portion of the skin exclusively with light of a desired wavelength (e.g., from about 390 nm to about 430 nm, and contacting the at least a portion of the skin with an anti-oxidant serum composition. | 08-05-2010 |
20100203029 | LYSYL OXIDASE-LIKE 1 (LOXL1) AND ELASTOGENESIS - Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers. | 08-12-2010 |
20100209412 | OSTEOGENESIS PROMOTER - It is intended to provide an osteogenesis promoter capable of promoting osteogenesis by promoting the differentiation of osteoblasts, and foods, drinks, drugs or feeds for promoting osteogenesis. Namely, an osteogenesis promoter capable of promoting osteogenesis by promoting the differentiation of osteoblasts which comprises, as the active ingredient, lactoperoxidase and/or a digestion product obtained by digesting lactoperoxidase with a protease such as trypsin; and foods, drinks, drugs or feeds for promoting osteogenesis containing lactoperoxidase and/or its digestion product. | 08-19-2010 |
20100215633 | Method for feeding dairy cows and dairy goats supplements to increase the C2 hxroylated estrogen (C2) to C16 hydroxlated estrogen (C16) ratio secreted in their urine - A feed supplement for dairy cows and goats containing various combinations of whole soy, muscadine grapes, Kudzu leaves, | 08-26-2010 |
20100239555 | Enzymatically active compositions for suppressing sulfide generation and methods of use thereof - The present invention provides an enzymatically active composition for suppressing sulfide generation. The composition is free from sulfur dehydrogenase and comprises at least one enzyme having sufficient sulfide-production inhibiting activity in an acidic medium to at least inhibit biogenic sulfide production, and an oxidized nitrogenous inorganic salt present in an amount sufficient to act as an electron acceptor for the enzyme. The oxidized nitrogenous inorganic salt preferably is selected from an alkali metal nitrite, an alkaline earth metal nitrite, an alkali metal nitrate, an alkaline earth metal nitrate, or a mixture of two or more of the foregoing salts. The enzymatically active composition is free from viable bacteria and is non-toxic (i.e., has an oral LD | 09-23-2010 |
20100239556 | PROMOTING ECM PRODUCTION BY FIBROBLAST CELLS AND/OR PROMOTING MIGRATION OF FIBROBLAST CELLS IN A BIOLOGICAL SYSTEM - The present invention relates to a method of promoting production of one or more components of extracellular matrix by one or more fibroblast cells in a biological system and/or promoting migration of one or more fibroblast cells in a biological system. The method includes exposing one or more fibroblast cells in the biological system to an effective amount of an agent with peroxidase activity. | 09-23-2010 |
20100247506 | FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING - The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm | 09-30-2010 |
20100247507 | INSTANT ENZYME FORMULATIONS FOR ANIMAL NUTRITION - The invention relates to a process for preparing an instant enzyme formulation; instant enzyme formulations obtainable by this process and feedstuff compositions prepared using instant enzyme formulations of the invention. | 09-30-2010 |
20100260737 | COMBINATION BETWEEN AN ISOTHIOCYANATE AND LEVODOPA FOR PARKINSON'S DISEASE TREATMENT - A combination between levodopa and an extract derived from a vegetable of the Cruciferae family or | 10-14-2010 |
20100266566 | TREATMENTS INVOLVING GLUTAREDOXINS AND SIMILAR AGENTS - The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like. | 10-21-2010 |
20100266567 | USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS - The invention relates to the use of a urate oxidase, preferably recombinant urate oxidase, for example rasburicase, for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure. | 10-21-2010 |
20100266568 | EC SOD AND USE THEREOF - The present invention relates to an EC SOD and the use thereof. More particularly, the present invention relates to an EC SOD and the use thereof for preventing or treating skin diseases, particularly dermatitis or psoriasis. | 10-21-2010 |
20100284987 | TABLETTABLE FORMULATIONS OF LIPOPHILIC HEALTH INGREDIENTS - The present invention is directed to a formulation of a lipophilic health ingredient comprising a lipophilic health ingredient, a protective colloid comprising a modified starch and an emulsifier. The present invention is further directed to a formulation of (a) lipophilic health ingredient(s) comprising (a) lipophilic health ingredient(s) and a protective colloid, wherein said protective colloid is a modified starch, characterized in that the formulation has a residual moisture content ≦6.5 weight-%, based on the total weight of the formulation, as well as to a process for their manufacture. The latter formulations are especially suitable for the preparation of stable tablets of these lipophilic health ingredients. | 11-11-2010 |
20100284988 | UTILIZATION OF SHIELD EFFECT FOR DOPAMINE DETECTION AND REAGENT DEVELOPMENT - The present invention relates to fusion proteins of monoamine oxidase B (MAO B)-green fluorescent protein (GFP) and utilizes “shield effect” to detect the dopamine under physiological condition, providing the reagent and method for dopamine detection. | 11-11-2010 |
20100284989 | 15-PGDH IN COLON CANCER - The disclosure provides, among other things, a method of decreasing resistance to the chemopreventive properties of non-steroidal anti-inflammatory agents, e.g., celecoxib, particularly in the prevention of cancer, e.g., colon cancer, by increasing the levels or activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The disclosure also provides a method of identifying compounds that upregulate or reactivate 15-PGDH. The disclosure also provides a method of identifying an individual suitable for treatment with a non-steroidal anti-inflammatory agent in the treatment or prevention of colon cancer. | 11-11-2010 |
20100303790 | USE OF BILIVERDIN REDUCTASE (BVR) AND BVR PEPTIDE FRAGMENTS TO TREAT CORONARY DISORDERS - The present invention relates to methods and compositions for treating coronary disorders and preventing cardiac cell death that involve the use of biliverdin reductase (“BVR”) or BVR peptides to stabilize the expression and activity of intracellular HO-2 in cardiac cells. The present invention also relates to methods and compositions for inducing cancer cell death in a patient having cancer that involve the use of inhibitory BVR peptides to destabilize intracellular HO-2 expression and activity, thereby augmenting cell death. | 12-02-2010 |
20100310541 | Compositions and Methods for Reducing the Toxicity of Certain Toxins - Compositions and methods for reducing the toxic effect of certain peptide toxins by administering an agent that directly or indirectly reduces disulfide bonds that are important for maintaining the toxin in an active conformation. Also described are compositions and methods for reducing the toxic effect of toxins that contain a heavy metal using an agent that destabilizes the binding of a metal ion that is important for toxin activity. | 12-09-2010 |
20100316621 | PROPHYLATIC AGENT FOR AUTOIMMUNE DISEASE - Provided is a prophylactic agent for an autoimmune disease, including a fraction of a milk-derived basic protein, lactoperoxidase, and lactoferrin as active ingredients. The agent can be taken on a daily basis, and even if it is taken over a long period of time, its safety is high, and hence, an autoimmune disease such as type I diabetes mellitus or rheumatoid arthritis, which could not be effectively prevented or treated by a conventional method, can be prevented. | 12-16-2010 |
20100316622 | DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS - Nitric oxide synthase deficiency causes diminished ryanodine receptor S-nitrosylation leading to increased diastolic calcium (Ca | 12-16-2010 |
20100316623 | PHENYLALANINE HYDROXYLASE FUSION PROTEIN AND METHODS FOR TREATING PHENYLKETONURIA - The present invention provides Phenylalanine Hydroxylase (PAH) fusion proteins and pharmaceutical compositions comprising the same, as well as encoding polynucleotides and vectors, and methods for treating hyperphenylalaninemia, including PKU, by enzyme replacement therapy. The fusion proteins have phenylalanine hydroxylase activity when administered: and have an increased half-life or persistence in circulation, as compared to unfused counterparts. The PAH fusion proteins are suitable for enzyme replacement therapy in PKU patients by converting phenylalanine in the circulation to tyrosine, thereby controlling phenylalanine levels. | 12-16-2010 |
20100330061 | Methods and Devices for Treating Lung Dysfunction - Methods and devices useful for treatment of lung conditions resulting from dysfunction of normal pulmonary physiology. | 12-30-2010 |
20110008310 | METHODS AND COMPOSITIONS FOR MITOCHONDRIAL REPLACEMENT THERAPY - The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities. | 01-13-2011 |
20110014174 | Lysozyme, A Novel Vasodilator of Sepsis that can be inhibited by a Peroxidase and Hydroxyl Radical Scavengers - A method of reducing a vasodilatory response comprising administering to an individual in need of such treatment an effective amount of a guanylate cyclase pathway inhibitor selected from the group consisting of methylene blue, ODQ, LY83583 and a protein kinase G inhibitor or an H | 01-20-2011 |
20110014175 | STIMULATION OF THE SYNTHESIS OF THE ACTIVITY OF AN ISOFORM OF LYSL OXIDASE-LIKE LOXL FOR STIMULATING THE FORMATION OF ELASTIC FIBRES - The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. | 01-20-2011 |
20110014176 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID - This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject. | 01-20-2011 |
20110027250 | Sealants for Fetal Membrane Repair - The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant. In one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane. | 02-03-2011 |
20110027251 | NOVEL USES FOR 4-PHENYLBUTYRATE (4PBA) AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS - Novel uses for 4-phenylbutyrate (4PBA) and its pharmaceutically acceptable salts | 02-03-2011 |
20110052557 | PHYTOCOMPOSITION HAVING ANTIMICROBIAL ACTIVITY - The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target. | 03-03-2011 |
20110070216 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES - Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress. | 03-24-2011 |
20110070217 | COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION WITH CUPREDOXIN AND CYTOCHROME C - The present invention relates to cupredoxin, specifically | 03-24-2011 |
20110091438 | RADIOPROTECTIVE SOD SOLUBLE ISOFORM AND USES THEREOF - The invention refers to a specific isoform of MnSOD (Mn-superoxide dismutase) and its uses for protecting and curing subjects exposed to radiations, specifically space radiations. | 04-21-2011 |
20110110913 | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS - A method of inducing NAD+ synthesis in a subject. The method comprises administering to the subject a therapeutically effective amount of resveratrol or a functionally equivalent analogue or derivative thereof. NAD+ synthesis increases the activity of Poly(ADP-ribose) polymerase (PARP) enzymes and sirtuin enzymes. The PARP enzyme is PARP-1 or PARP-2 and the sirtuin enzyme is selected from the group consisting of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7. | 05-12-2011 |
20110117071 | Antimicrobial Composition - The present invention relates to an improved antimicrobial composition comprising a hydrogen peroxide source and one or more antimicrobial agents. Ideally, the invention relates to an antimicrobial composition comprising (i) hydrogen peroxide source and (ii) an antimicrobial agent and its associated use in therapy, particularly in the treatment of antimicrobial infections. | 05-19-2011 |
20110135622 | Presbyopia Treatment by Lens Alteration - This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule. | 06-09-2011 |
20110150856 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen. | 06-23-2011 |
20110165138 | PROTOCOLS FOR TREATING AND PREVENTING OBESITY AND COMPLICATIONS ARISING THEREFROM - The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes. | 07-07-2011 |
20110165139 | GROWTH HORMONE SECRETION STIMULATOR - Provided are: an agent for promoting growth hormone-secretion, containing a milk-derived basic protein fraction as an active ingredient, with the promotion of growth hormone-secretion being mediated by the promotion of secretion of ghrelin having an effect for promoting growth hormone-secretion; and a method of promoting the secretion of ghrelin by using a milk-derived basic protein fraction. The agent for promoting growth hormone-secretion may be ingested on a daily basis and is highly safe even with its ingestion for a long period. | 07-07-2011 |
20110171192 | SUBSTITUTED AMINE DERIVATIVE AND MEDICINAL COMPOSITION COMPRISING SAME AS THE ACTIVE INGREDIENT - A compound represented by following general formula (I): | 07-14-2011 |
20110171193 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - Provided herein are methods and materials for treating pulmonary hypertension (PH) in a subject. Also provided herein is a method of diagnosing whether a has PH by detecting a PH marker. A PKG pulmonary hypertension marker has been identified and may be useful in predicting PH disease progression and assessing a subject's response to PH therapy. | 07-14-2011 |
20110171194 | METHODS AND COMPOSITIONS FOR INHIBITING ABAD/ABeta PROTEIN INTERACTION - This invention provides methods, compositions and articles of manufacture for inhibiting binding between Aβ protein and ABAD in cells. Uses of this invention include, for example, treating Alzheimer's disease; reducing free radical generation, DNA fragmentation, and cytochrome C release in cells; and preserving cell viability by preventing LDH release from a cell. | 07-14-2011 |
20110177054 | USE OF ENDO-LYSOSOMAL SYSTEM AND SECRETED VESICLES (EXOSOME-LIKE) IN TREATMENTS AND DIAGNOSTICS BASED ON SMALL RNA AND EXPERIMENTAL STUDY OF SMALL RNA - The present invention relates to a method for determining the delivery rates and/or efficiency of a siRNA, miRNA or related molecule to target organs or cells, a kit and the use of proteins or lipids involved in the formation of the endolysosomal system for modulating the activity and/or the cell-to-cell transfer of RNA, small RNA, for example miRNA, siRNA and piRNA, mRNA or non-coding RNA. | 07-21-2011 |
20110189154 | Applications For A New Class Of Enzymes: Sulfiredoxins - Applications of a new class of enzymes, sulfiredoxines (Srx), catalyzing the reduction of Cys-SO | 08-04-2011 |
20110206653 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 08-25-2011 |
20110212072 | Inhibitors of Fatty Acid Oxidation for Prophylaxis and Treatment of Diseases Related to Mitochondrial Dysfunction - Described are a method and a composition for preventing and/or treating a disease related to mitochondrial dysfunction by inhibiting the fatty acid oxidation of one or more cells of an organism. Particularly, the fatty acid oxidation is inhibited by inhibiting the expression and/or activity of the enzyme Camitin-Palmitoyl-Transferase-1 (CPT-1) by means of an arylalkyl- or arlyoxyalkyl-substitued oxirane carboxylic acid or pharmaceutically acceptable salts and derivatives of the arylalkyl-substituted oxirane carboxylic acid. | 09-01-2011 |
20110217279 | USE OF HUMAN BILIVERDIN REDUCTASE AND FRAGMENTS THEREOF FOR THE TREATMENT OF PROTEIN KINASE C-DELTA AND ERK RELATED CONDITIONS - The present invention is directed to methods of modulating PKC-δ activity and PKC-δ/ERK complex activity in cells via biliverdin reductase. Methods and compositions for diagnosing and treating a PKC-δ and PKC-δ/ERK complex related condition are also disclosed. | 09-08-2011 |
20110229449 | PROPHYLAXIS AND TREATMENT OF MACULAR DEGENERATION AND RETINOPATHY USING A PRDX PROTEIN - The present invention provides an agent for the prophylaxis or treatment of retinopathy or AMD containing PRDX 5 or PRDX 6, as well as an agent for the prophylaxis or treatment of retinopathy or AMD containing a polynucleotide encoding PRDX 5 or PRDX 6. The present invention also provides a method for the prophylaxis or treatment of retinopathy or AMD in a patient suffering from the disease, which includes administering to the patient an effective amount of PRDX 5 or PRDX 6, or administering to the patient an effective amount of a polynucleotide encoding PRDX 5 or PRDX 6. | 09-22-2011 |
20110236365 | METHOD FOR PROTECTING AND TREATING AT LEAST ONE MUSCARINIC RECEPTOR FROM DYSFUNCTION RESULTING FROM FREE RADICAL DAMAGE - Methods and compositions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds. | 09-29-2011 |
20110243911 | USE OF A COMPOUND CAPABLE OF REDUCING THE URIC ACID LEVEL FOR THE PREVENTION AND/OR THE TREATMENT OF LUNG INFLAMMATION AND FIBROSIS - The present invention is directed to the use of a compound capable of reducing the uric acid level in a mammal for the prevention and/or the treatment of IL-1β driven lung pathology, particularly to treat lung inflammation such as chronic fibrosis, COPD and interstitial fibrosis and other IL-1β driven lung pathologies including those of autoimmune origin. Preferred compounds capable of reducing the uric acid level are selected from the group consisting of xanthine oxidase inhibitors, such as allopurinol, recombinant enzyme uricase and uricosuric compound capable of enhancing uric acid excretion, such as probenecid. The invention further relates to a method for identifying in vitro whether a patient presents an IL-1β driven lung pathology or is at risk to develop an IL-1β driven lung pathology, or for the screening of a compound for treating an IL-1β driven lung pathology. | 10-06-2011 |
20110262420 | INHALANT COMPRISING MODIFIED SUPEROXIDE DISMUTASE - An inhalant containing a lecithinized superoxide dismutase (hereinafter referred to as PC-SOD) which effectively exerts the effect of superoxide dismutase (SOD) as an active ingredient, particularly for treatment of idiopathic (acute) or chronic interstitial pneumonia, is provided. The inhalant includes a PC-SOD represented by the following general formula (I): | 10-27-2011 |
20110262421 | PHARMACEUTICAL COMPOSITION, FOOD OR DRINK, OR FEED FOR INTESTINAL DISEASE - It is intended to provide a pharmaceutical composition, a food or drink, or a feed which has an effect on the prevention and/or treatment of an intestinal disease such as ulcerative colitis, Crohn's disease or irritable bowel syndrome. A preferred embodiment is the pharmaceutical composition, food or drink, or feed which contains lactoperoxidase as an active ingredient and has an effect on the prevention and/or treatment of an intestinal disease, wherein the intestinal disease is at least one disease selected from ulcerative colitis, Crohn's disease and irritable bowel syndrome. | 10-27-2011 |
20110268719 | Annatto Extract Compositions, Including Geranyl Geraniols And Methods Of Use - Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required. | 11-03-2011 |
20110274680 | Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases - Synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases; chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease and a targeted nano delivery of bioactive compounds and/or bioactive molecules are described. Furthermore, microelectro-mechanical system (Mems) based passive and active (based on feedback diagnostics data) delivery systems and methods of bioactive compounds and/or bioactive molecules are also described. | 11-10-2011 |
20110280855 | VITAMIN C COMPOSITIONS - The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives, and at least one ascorbate-glucose transport enhancer in an amount from about 0.01% by weight of actives to about 99.0% by weight of actives. In other aspects, methods of improving the transport of ascorbate into cells and tissues, and improving the ascorbate or antioxidant status of a person, are provided that include providing a composition comprising ascorbate and at least one ascorbate-glucose transport enhancer. | 11-17-2011 |
20110286990 | METHODS OF DIAGNOSING AND TREATING FIBROSIS - The present invention is directed to methods of diagnosing and treating a fibrotic condition in a mammalian subject. These methods involve measuring the levels of trimethylation at lysine residue 27 of histone-3 and/or measuring the expression levels of EZH2 or YY-1. Agents useful for treating fibrosis or a fibrotic condition are also disclosed. | 11-24-2011 |
20110286991 | PEPTIDES DERIVED FROM HMG-COA REDUCTASE AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to peptides derived from human HMG-CoA reductase of general formula (I): | 11-24-2011 |
20110286992 | PERSONAL CARE COMPOSITION CONTAINING LEGHEMOGLOBIN - A personal care composition comprising leghemoglobin and at least one preservative selected from the group consisting of alcohols, glycols, parabens, hydantoins, quaternary nitrogen-containing compounds, isothiazolinones, aldehyde-releasing agents, and halogenated compounds. Preferably, the leghemoglobin is a nitrogen fixation root nodule extract providing a leghemoglobin concentration in the composition of between 0.0001% and about 10% based upon the total weight of the composition. Also disclosed is a method for preparing the personal care composition. | 11-24-2011 |
20110293592 | METHOD OF TREATING CORONARY ARTERIES WITH PERIVASCULAR DELIVERY OF THERAPEUTIC AGENTS - A method of treating the intraluminal disease in a coronary artery by injecting therapeutic agents perivascularly into the myocardium near the site of disease. | 12-01-2011 |
20120020946 | Methods for Inactivating Viruses - The present invention provides a method for inactivating viruses, by contacting the viruses with a haloperoxidase, hydrogen peroxide, chloride ions, bromide ions, and ammonium ions. | 01-26-2012 |
20120034203 | Methods for Killing or Inhibiting Growth of Mycobacteria - The present invention provides a method for killing or inhibiting growth of Mycobacteria, by contacting the Mycobacteria with a haloperoxidase, hydrogen peroxide, chloride ions and/or bromide ions, and ammonium ions. | 02-09-2012 |
20120058099 | USE OF HYPOXANTHINE FOR PROMOTION OF NEURONAL OUTGROWTH - Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve growth factor (NGF), and/or in the absence of exogenous D-mannose, and/or in the absence of exogenous oncomodulin, and/or in the absence of exogenous TGF-B. The neuron may be an optic nerve neuron or a retinal neuron and/or an injured neuron. Neurons may be from the central nervous system (CNS) or the peripheral nervous system (PNS). The methods are useful for treating an injured neuron, for example to an optic nerve neuron, resulting from branch and central vein/artery occlusion, trauma, edema, angle-closure glaucoma, open-angle glaucoma. Methods of treatment of various neurological injuries and diseases, as well as therapeutic compositions, are also disclosed. | 03-08-2012 |
20120058100 | MODULATION OF DRUG RELEASE RATE FROM ELECTROSPUN FIBERS - Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically active agents and/or biologically active agents. Also disclosed are processes of delivering pharmaceutically active agents and/or biologically active agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 03-08-2012 |
20120058101 | TREATMENT OF HUMAN OR ANIMAL BODY SURFACE INFECTION - A method of treatment of a human or animal body surface infection, particularly a fungal infection, comprises applying an aqueous liquid to the infected body surface, e.g. nail region, followed by applying a dressing comprising a source of hydrogen peroxide. Also provided is a combination of the liquid and dressing for use in the method. | 03-08-2012 |
20120076766 | Topical drug delivery system with dual carriers - A method of selecting the constituent elements of a therapeutic composition for application to wounds having a pathogen load is disclosed. The method includes selecting a pharmaceutical active agent selected from a list of pharmaceutical active agents approved for over the counter non-prescription use, and said pharmaceutical active agent having suitable activity to kill the desired pathogens; identifying a tissue permeation enhancer from a list of generally recognized and safe tissue permeation enhancers that facilitates penetration of a composition using the selected tissue permeation enhancer through the stratum corneum of mammalian tissue; selecting a hygroscopic carrier agent suitable for mixing in solution with the tissue permeation enhancer and the pharmaceutical active agent; said hygroscopic carrier agent being selected from a list of generally recognized and safe hygroscopic carrier agents; and ensuring that the activity/water (A | 03-29-2012 |
20120082654 | Method For Preventing And Controlling Organisms That Infest Aqueous Systems - Method for preventing and controlling organisms that infest aqueous systems in which one or more organic or inorganic compounds capable of releasing gas are present, comprising the step of dispersing on and/or in the aqueous mass a preparation comprising enzymes adapted to catalyze a reaction of the one or more compounds that leads to the formation of gas. | 04-05-2012 |
20120093796 | NOVEL USE OF EC-SOD AND METHOD FOR PREPARING THEREOF - The present invention relates to compositions for preventing or treating angiogenesis-mediated diseases or allergic diseases which contain, as an active ingredient, an EC-SOD protein or a vector having a polynucleotide encoding thereof. The EC-SOD protein or the vector having a polynucleotide encoding the EC-SOD protein has the effect on inhibiting angiogenesis by inhibiting the expression of VEGF and MMP-9 which induce angiogenesis. Therefore, the EC-SOD protein or the vector may be useful for preventing or treating angiogenesis-mediated diseases. And the EC-SOD protein or the vector having a polynucleotide encoding said EC-SOD protein also has the effect on inhibiting over-differentiation of Th2 cells which cause allergic diseases, inhibiting transcription factor (NF-κ B), and reducing degranulation of human mast cells. Accordingly, the EC-SOD protein or the vector may be useful for preventing or treating allergy diseases. In addition, the inventive method for preparing an EC-SOD protein may be used in preparing an EC-SOD protein having the activity on a large scale. Therefore, the inventive method may be useful industrially. | 04-19-2012 |
20120100122 | COMBINATION THERAPY - A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders. | 04-26-2012 |
20120100123 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ | 04-26-2012 |
20120100124 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER - The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer. | 04-26-2012 |
20120121568 | SUPEROXIDE DISMUTASE VARIANTS AND METHODS OF USE THEREOF - The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity. | 05-17-2012 |
20120128650 | EXTENDED ACTING OXYGEN GENERATING COMPOSITION FOR TREATING MICROBIAL INFECTIONS - A medicament for the treatment or prevention of a microbial infection or an associated condition in a low oxygen environment characterised in that the medicament includes an extended acting oxygen generating system. | 05-24-2012 |
20120171189 | Polypeptides of Botryosphaeria Rhodina - The invention relates to functional polypeptides secreted from | 07-05-2012 |
20120177626 | HDL COMPRISING A THERAPEUTIC AGENT AND USE IN THERAPY - The present invention provides an HDL comprising an agent selected from the group consisting of antiproteases, antixoxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use as a medicament. | 07-12-2012 |
20120189602 | Treatment and prevention of pulmonary conditions - The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants. | 07-26-2012 |
20120189603 | STORAGE-STABLE, SYNERGISTIC MICROBICIDAL CONCENTRATES CONTAINING AN ISOTHIAZOLONE, AN AMINE AND AN OXIDIZING AGENT - A microbicidal composition in the form of a concentrate includes a) one or more isothiazolin-3-ones, b) one or more organic amines with an alkyl group having at least 8 carbon atoms and c) one or more oxidizing agents. The concentrate is storage-stable and is used for the preservation of technical and domestic products. | 07-26-2012 |
20120195873 | METHODS OF ATTENUATING THE LOSS OF FUNCTIONAL STATUS - Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition including whey protein, and Vitamin D. The nutritional composition and exercise can be specifically used to attenuate the loss of functional status, especially in the elderly. | 08-02-2012 |
20120201803 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID - A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 μm forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker. | 08-09-2012 |
20120219536 | PURINE-TARGETED DIAGNOSIS AND THERAPY OF WOUNDS - Methods of treating a wound, an ulcer and/or a burn responsive to inhibition of xanthine oxidoreductase to thereby reduce uric acid in an animal are provided wherein the methods include topical administration of a therapeutic agent effective for treatment of the wound, the ulcer and/or the burn wherein the therapeutic agent inhibits xanthine oxidoreductase to thereby reduce uric acid in the wound, ulcer and/or burn. Also provided are methods and kits for determining the severity of a wound, a burn and/or an ulcer including the step of detecting one or more of (i) a level of uric acid; (ii) a level of one or more uric acid precursors; and (iii) a presence, or absence of or level of xanthine oxidoreductase. | 08-30-2012 |
20120244138 | ANTIDOTES FOR NITROBENZODIAZEPINES - Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants. | 09-27-2012 |
20120269795 | HUMANIZED RECOMBINANT URICASE AND MUTANTS THEREOF - The present invention provides a humanized recombinant uricase and mutants thereof, wherein the humanized recombinant uricase is a chimeric protein which comprises amino acids of non-human mammal uricase and amino acids of human uricase. The humanized recombinant unease and mutants thereof have reduced immunogenicity in human, and can be used for the treatment of hyperuricemia and gout. | 10-25-2012 |
20120288487 | BIODEGRADABLE PAOX POLYMER PARTICLE WITH CATIONIC PROPERTY - The present invention relates to the preparation of poly(amino oxalate) (PAOX) using oxalyl chloride, 1,4-cyclohexanedimethanol, and piperazinediethanol, the preparation of biodegradable polymer particles using the PAOX, and the use of PAOX particles as a drug delivery vehicle. The PAOX according to the present invention is a polymer that has three characteristics of biodegradability, biocompatibility, and cationic properties at the same time with appropriate hydrophobicity and thus can be prepared as particles that allow rapid drug release. Moreover, the particles improve the delivery efficiency of a drug into cells and thus can be efficiently used as a drug delivery vehicle for the treatment of acute inflammatory diseases such as acute liver failure and acute lung injury. | 11-15-2012 |
20120328593 | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites - The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme. | 12-27-2012 |
20120328594 | PROTEIN AND LIPID BIOMARKERS PROVIDING CONSISTENT IMPROVEMENT TO THE PREDICTION OF TYPE 2 DIABETES - The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions. | 12-27-2012 |
20130004477 | Methods for Treating Inflammation and Oxidative Stress Related Diseases - This invention provides compositions and methods for treating inflammation related diseases. Particularly, the present invention provides methods and compositions of administering thiocyanate to treat inflammation related diseases, such as cystic fibrosis, lung disease, lung cancer, asthma, bronchitis, pancreatic disease, digestive track disease, diabetes, neurological disorder, cardio-vascular disease, atherosclerosis, arthritis, nephritis, or stroke, and neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or autism. The invention provides the use of thiocyanate to diagnose inflammation related diseases. | 01-03-2013 |
20130011379 | Pyridoxamine for the Treatment of Diabetic Kidney Disease - The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient. | 01-10-2013 |
20130058911 | REDUCING AGENT FROM MICROORGANISM BELONGING TO GENUS BACILLUS AND APPLICATION FOR SAME - The present invention is intended to provide a reducing agent effective for color development of meat and uses therefor. The present invention provides a reducing agent containing a heme reductase derived from a microorganism belonging to the genus | 03-07-2013 |
20130071371 | Method of Producing Physiological and Therapeutic Levels of Nitric Oxide Through an Oral Delivery System - A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity. | 03-21-2013 |
20130071372 | METALLO-PROTEIN AND TOCOTRIENOL (MP-T3) COMPOSITIONS WITH NON-PROTEIN-TYPE METAL CHELATOR AND USES THEREOF - Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements. | 03-21-2013 |
20130089534 | METHODS FOR ASSISTING ANTI-CANCER DRUGS - A method for assisting an anti-cancer drug comprising administrating an effective amount of | 04-11-2013 |
20130089535 | AGENT FOR REDUCING ACETALDEHYDE IN ORAL CAVITY - Disclosed herein is a novel enzymatic agent effective in reducing acetaldehyde in the oral cavity. It has been found that an aldehyde dehydrogenase derived from a microorganism belonging to the genus | 04-11-2013 |
20130101571 | ANTIDOTES FOR NITROBENZODIAZEPINES - Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants. | 04-25-2013 |
20130101572 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen. | 04-25-2013 |
20130108607 | Methods and Compositions for Treating Oxalate-Related Conditions | 05-02-2013 |
20130136726 | METHOD FOR DETECTION OF PREDISPOSITION TO ATHEROSCLEROSIS, CORONARY HEART DISEASE AND RELATED CONDITIONS - Heteroplasmy mitochondrial DNA (mtDNA) markers and haplotypes of susceptibility or predisposition to atherosclerosis, coronary heart disease (CHD) and subdiagnosis of atherosclerosis and CHD and related medical conditions are disclosed. The biomarkers may be selected from the following heteroplasmy makers: 652lns/del G; A1555G; C3256T; T3336C; G12315A; G13513A; G14459A; G14846A; G15059A. Methods and kits for diagnosis, subdiagnosis, and prediction of clinical course and efficacy of treatments for CHD, atherosclerosis and related phenotypes using heteroplasmy in the risk genes and loci and other related biomarkers are thus provided. Novel methods for prevention and treatment of atherosclerosis, CHD and related conditions based on the disclosed CHD genes, loci, polypeptides and related pathways are also provided. | 05-30-2013 |
20130171123 | METHODS FOR PURIFICATION, USE AND ANALYSIS OF FERRITIN - This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin. | 07-04-2013 |
20130183281 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2). | 07-18-2013 |
20130195830 | PERORALLY APPLICABLE PREPARATION CONTAINING HISTAMINASE OF VEGETABLE ORIGIN, RESISTANT TO PEPSIN AND TRYPSIN AND A PROCESS FOR PRODUCING IT - The subject of the invention is a perorally applicable preparation of vegetable origin, resistant to pepsin and trypsin, based on histaminase, optionally for the use as an agent for improving digestion, reducing appetite or reducing body weight. The preparation of the invention is a pressed juice—which is optionally in lyophilized form—obtained from seedlings of pea ( | 08-01-2013 |
20130195831 | SILK-BASED DRUG DELIVERY SYSTEM - The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer. | 08-01-2013 |
20130202573 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 08-08-2013 |
20130209432 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 08-15-2013 |
20130209433 | MODULATION OF AMINO ACID METABOLISM IN THE HYPOTHALAMUS - Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal. | 08-15-2013 |
20130216514 | COMPOSITIONS COMPRISING GLUTATHIONE REDUCTASE AND OXIDIZED GLUTATHIONE - Compositions comprising Glutathione Reductase (GSSG-r) and Oxidized Glutathione (GSSG) or pharmaceutically acceptable salts thereof for pharmaceutical use as antiviral and antibacterial agents and for the protection against the toxicity of free radicals and in particular radicals produced by the radiolysis of cellular water are provided. Methods of making and using such compositions are also provided. | 08-22-2013 |
20130259850 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. | 10-03-2013 |
20130273023 | DETECTION, ISOLATION AND USES OF RENALASE (MONOAMINE OXIDASE C) - The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase. | 10-17-2013 |
20130280229 | Stabilisation of Proteins - A dry composition for use in therapy or diagnosis, obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffer has a pK | 10-24-2013 |
20130295074 | Pyridoxamine for the Treatment of Diabetic Kidney Disease - The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient. | 11-07-2013 |
20130302305 | Methods for Treating Gout in Patients Subpopulations - The present application discloses a method of lowering serum uric acid level in a subject with impaired renal function, comprising administering to the subject a compound of Formula (I), as disclosed herein. | 11-14-2013 |
20130315889 | CARTILAGE OLIGOMERIC MATRIX PROTEIN (COMP)-GROWTH FACTOR COMPLEXES AND USES THEREOF - The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions. | 11-28-2013 |
20130330314 | Metal Abstraction Peptide With Superoxide Dismutase Activity - Compositions comprising peptides that are capable of binding a metal are disclosed. Such compositions can be used for binding metal in a variety of contexts and environments. In various embodiments, peptides are used for antioxidant activity, anti-inflammatory activity, anti-pain therapy, as chemical reagents, and/or as superoxide dismutase mimics. | 12-12-2013 |
20130336949 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 12-19-2013 |
20130336950 | MATERIAL COMBINATION FOR TREATING INFLAMMATORY OR INFECTIOUS DISEASES - A material combination is configured to treat or prevent inflammatory and infectious diseases caused by fastidious anaerobic or facultative anaerobic microorganisms, such as bacteria or | 12-19-2013 |
20130336951 | COMPOSITIONS AND METHODS FOR MODULATING AMPA RECEPTOR-MEDIATED EXCITOTOXICITY - The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are also disclosed. | 12-19-2013 |
20130344053 | Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides - The present invention relates to a method of modulating insulin signaling in a cell. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, modulates insulin signaling in the cell via biliverdin reductase interaction with one or both of insulin receptor kinase domain and insulin receptor substrate. Also disclosed are methods of treating a condition associated with insulin signaling and treating a patient for a condition associated with insulin-mediated glucose uptake. | 12-26-2013 |
20140017221 | Superoxide Dismutase Variants and Methods of Use Thereof - The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity. | 01-16-2014 |
20140017222 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ | 01-16-2014 |
20140037608 | INSECTICIDAL PROTEIN, GENE ENCODING THE SAME AND USES THEREOF - The invention relates to an insecticidal protein, its gene encoding and the uses thereof. The protein comprises: (a) a protein consisting of an amino acid sequence shown by SEQ ID NO:2; or (b) a protein derived from (a) consisting of an amino acid sequence by substitution, deletion, or addition of one or more amino acid residues of the amino acid sequences in (a), and having insecticidal activity; or (c) a protein generated by the expression of nucleic acid molecules containing a nucleotide sequence of SEQ ID NO:1; or (d) a protein generated by the expression of nucleic acid molecules containing a complementary sequence that hybridized with SEQ ID NO:1 under stringent conditions; or (e) a protein generated by the expression of nucleic acid molecules that contain nucleotide sequences isocoding with the nucleotide sequences in (d). The insecticidal protein of the invention has high expression level and strong toxicity against pests. | 02-06-2014 |
20140037609 | INSECTICIDAL PROTEIN, GENE ENCODING THE SAME AND USES THEREOF - The invention relates to an insecticidal protein, its gene encoding and the uses thereof. The protein comprises: (a) a protein consisting of an amino acid sequence shown by SEQ ID NO:2 or a sequence of amino acid residuses at positions 1 to 640 thereof; or (b) a protein derived from (a) by substitution, deletion, or addition of one or more amino acid residuses of the amino acid sequences in (a), and having insecticidal activity; or (c) a protein generated by the expression of nucleic acid molecules containing a sequence of amino acid residuses at the positions 1 to 1920 of SEQ ID NO:1; or (d) a protein generated by the expression of nucleic acid molecules containing a complementary sequence that hybridized with the sequence of nucleotides at the positions 1 to 1920 of SEQ ID NO:1 under stringent conditions. The protein has high expression level and strong toxicity against pests. | 02-06-2014 |
20140120076 | EOSINOPHIL PEROXIDASE COMPOSITIONS AND METHODS OF THEIR USE - Eosinophil peroxidase compositions and methods of their use for killing and/or inhibiting the growth of susceptible microorganisms are provided. The compositions include an eosinophil peroxidase, a peroxide or peroxide source, and amino acids glycine, L-alanine, and L-proline. | 05-01-2014 |
20140134148 | Brucella Abortus Proteins and Methods of Use Thereof - Compositions and methods for the diagnosis and prevention of | 05-15-2014 |
20140147430 | APPLICATION FOR PRDX2 AND/OR PRDX6 IN PREPARATION OF PHARMACEUTICAL COMPOSITION TO TREAT OR PREVENT DAMAGE, AGING OR DISEASE RESULTING FROM INCREASE OF REACTIVE OXYGEN SPECIES - Provided in the present invention is an application for PRDX2 and/or PRDX6 in the preparation of a pharmaceutical composition to treat or prevent damage, aging or diseases resulting from an increase in reactive oxygen species (ROS). | 05-29-2014 |
20140161785 | Verticillin A Inhibition of Histone Methyltransferases - Verticillin A is found to be a potent inhibitor of histone methyltransferases, selective for G9a, GLP, SUV39H1, SUV39H2, MLL1, and NSD2. Methods of using Verticillin A are provided. The Verticillin A can be synthetically produced or it can be isolated from natural sources. Methods if inhibiting one or more histone methyltransferases are provided. In addition, methods are provided for treating diseases or disorders related to overexpression of one or more histone methyltransferases. Exemplary diseases and disorders to be treated include cancer, asthma, HIV, and progeria. | 06-12-2014 |
20140186324 | METHODS FOR ISOLATION, USE AND ANALYSIS OF FERRITIN - This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin. | 07-03-2014 |
20140248252 | New Salt And Medical Use - The present invention is directed to 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with elevated blood uric acid levels, such as hyperuricemia or gout. The invention is also directed to the tosylate salt of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide. | 09-04-2014 |
20140255379 | STABILIZED COMPOSITIONS AGAINST IONISING RADIATION - This invention relates to improvements to medical devices such as biosensors containing proteins such as oxidoreductases, for example oxidase and/or peroxidase enzymes. More generally it relates to novel compositions containing proteins which are stabilised to ionising radiation. | 09-11-2014 |
20140271599 | PRODUCT AND PROCESS FOR MUCUS VISCOSITY NORMALIZATION - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system. | 09-18-2014 |
20140286926 | METHOD FOR TREATMENT OR PREVENTION OF ALLERGIC DISEASES - The present invention provides a method for reducing an allergic response and treating or preventing an allergic disease, comprising administering a subject in need thereof a therapeutically effective amount of the active ingredient for the treatment or the prevention of allergic diseases, wherein the active ingredient is glyceraldehyde-3-phosphate Dehydrogenase (G3PDH) or the functional variant or fragment thereof. The G3PDH can be isolated from | 09-25-2014 |
20140308262 | Mitochondrial Proteins Constructs and Uses Thereof - The invention provides fusion protein constructs comprising a functional mitochondrial protein and methods of treating mitochondrial disorders by the fusion proteins and compositions thereof. | 10-16-2014 |
20140314733 | Product and Method for the Removal of Biofilms - Composition for the removal of biofilms present on a substrate, comprising at least one detergent component comprising at least one sequestering agent and at least one agent that is simultaneously a wetting and a dispersing agent, and at least one enzymatic component containing at least one protease, at least one laccase and at least one polysaccharidase | 10-23-2014 |
20140328821 | VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR - The present invention relates to nucleic acids coding for and capable of expressing a rod-derived cone viability factor (RdCVF) and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting an RdCVF, and methods of treatment. | 11-06-2014 |
20140335067 | NOVEL USE OF EC-SOD AND METHOD FOR PREPARING THEREOF - A method for treating a disease, particularly asthma and anaphylactic shock, comprises administering to a subject in need thereof an effective amount of an EC-SOD protein or a vector having a polynucleotide encoding thereof. | 11-13-2014 |
20140335068 | NOVEL USE OF EC-SOD FOR TREATING ANGIOGENESIS-MEDIATED EYE DISEASES - A method for treating an angiogenesis-mediated eye disease, includes administering to a subject in need thereof an effective amount of EC-SOD protein, or a vector having a polynucleotide encoding the EC-SOD protein, to treat angiogenesis-mediated eye diseases. | 11-13-2014 |
20140335069 | GLUCOSE-6-PHOSPHATE DEHYDROGENASE ASSAYS - Aspects of embodiments may include methods for automated enzymatic detection of glucose-6-phosphate dehydrogenase (G6PD) activity. Aspects of embodiments may include methods for enzymatic detection of G6PD activity in droplets in oil. Aspects of embodiments may include a system including a droplet actuator. Aspects of embodiments may include a treatment method. | 11-13-2014 |
20140348812 | PROTOCOLS FOR TREATING AND PREVENTING OBESITY AND COMPLICATIONS ARISING THEREFROM - The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes. | 11-27-2014 |
20140363414 | Aggregate-Free Urate Oxidase For Preparation of Non-Immunogenic Polymer Conjugates - A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates. | 12-11-2014 |
20150044190 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 02-12-2015 |
20150064158 | SENSE-IMPROVING AGENT - A purpose of the present invention is to provide a sense-improving agent which is safe and, when routinely taken or applied to the skin, exerts an effect of improving deterioration in peripheral sensation. Another purpose of the present invention is to provide a food, a drink, a feed or a cosmetic for improving sensation which exerts an effect of improving deterioration in peripheral sensation when orally taken or applied to the skin. The sense-improving agent comprises, as the active ingredient, a basic protein fraction derived from milk or a degraded basic protein fraction derived from milk. By orally taking the basic protein fraction derived from milk or the degraded basic protein fraction derived from milk or applying the same directly to the skin, deterioration in sensation, in particular, peripheral sensation can be improved. Thus, a food, a drink, a feed or a cosmetic for improving sensation can be obtained. | 03-05-2015 |
20150071904 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA - Provided herein are compositions and methods comprising ROS target modulators that increase ROS flux and endogenus ROS production, thereby potentiating oxidative attack by antibiotics and biocides. | 03-12-2015 |
20150118214 | Pharmaceutical composition containing human cyclooxygenase and doxorubicin or doxorubicin analogue, preparation method therefor and use thereof in preparing drugs - Provided are a pharmaceutical composition containing human cyclooxygenase and doxorubicin or a doxorubicin analogue using Salvia plectranthoides (also referred to as rare grass) as a crude drug, a preparation method therefor and the use thereof in preparing drugs for treating nephritis, cholecystitis and gallbladder polyps, tumours or antiphlogistic and analgesic drugs. | 04-30-2015 |
20150132275 | COMPOSITION FOR PREVENTING HEADACHES - The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches. | 05-14-2015 |
20150132276 | CARTILAGE REGENERATION-PROMOTING AGENT - It is an object of the present invention to provide a chondrogenesis promoter that is safe and exhibits a chondrogenesis-promoting effect by daily ingestion. It is also an object of the invention to provide a proteoglycan synthesis promoter that exhibits a proteoglycan synthesis-promoting effect by ingestion. Provided are a chondrogenesis promoter and a proteoglycan synthesis promoter each containing a milk-derived basic protein fraction as an active ingredient. Synthesis of proteoglycan and formation of a cartilage can be promoted by oral ingestion of the milk-derived basic protein fraction. A hydrolysate of the milk-derived basic protein fraction also has a similar chondrogenesis-promoting effect. | 05-14-2015 |
20150139973 | OPHTHALMOLOGICAL VEHICLE SYSTEM FOR DRUGS, OPHTHALMOLOGICAL KIT AND ALSO USE OF AN OPHTHALMOLOGICAL COMPOSITION - The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance. In addition, the use of a special ophthalmological composition as vehicle system, penetration accelerator, penetration enhancer, absorption enhancer/-improver/-accelerator for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals is the subject of the invention. Furthermore, the invention relates to a fluid dispenser which comprises an ophthalmological vehicle system according to the invention. | 05-21-2015 |
20150290298 | COMBINATION TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) - A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease. | 10-15-2015 |
20150297564 | METHOD OF ENHANCING GLUCOSE-STIMULATED INSULIN SECRETION AND OF TREATING TYPE 2 DIABETES OR HYPOGLYCEMIA - The present invention is directed to a method of enhancing glucose-stimulated insulin secretion in a subject. The method involves selecting a subject with: (1) an antioxidant deficiency and (2) a need for enhanced glucose-stimulated insulin secretion, and administering to the selected subject an agent selected from the group consisting of (1) a compound according to Formula I or a pharmaceutically acceptable salt thereof: | 10-22-2015 |
20150297682 | METHOD OF TREATING CANCER USING HIGH EFFICIENCY SELF-ILLUMINATIVE NANOCOMPLEXES AND METHOD OF MANUFACTURING THE SAME - The present disclosure relates to a method of treating cancer using a composition including a target-specific self-illuminative nanocomplex which includes an self-illuminative nanocomplex including a quantum dot and a modified self-illuminative protein (m-Rluc8), a targeted cancer-specific molecule and a hydrophilic polymer, and a method of preparing the composition. | 10-22-2015 |
20150299672 | RESTORING PHOSPHORYLATION OF A NOVEL PINK1 SUBSTRATE TO TREAT PARKINSON'S DISEASE - The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm. | 10-22-2015 |
20150314471 | WOOD PRESERVATIVE COMPOSITION - The present invention provides wood preservative composition containing a dispersed and/or emulsified phase comprising a wood preservative component; and a stabilizer. The stabilizer is a cationic polymer, an enzyme, organic polymer, quaternary ammonium compound and/or a mixture thereof. Also provided is a method of preserving wood or other cellulosic material which comprises applying to the wood or other cellulosic material. | 11-05-2015 |
20150322006 | PHENYLTHIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 11-12-2015 |
20150342909 | THERAPEUTIC COMPOUNDS AND METHODS - Biguanide compounds and salts thereof are disclosed. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as breast cancer. | 12-03-2015 |
20150344954 | Detection of Brain Injury - The present invention provides minimally invasive methods of detecting, diagnosing, and assessing neuronal damage associated with traumatic brain injury (TBI) or chronic traumatic encephalopathy (CTE). Specific species of microRNAs (miRNA), small, noncoding RNA molecules that play gene regulatory functions, are correlated with cellular damage and oxidative stress following TBI or CTE, allowing for rapid, minimally-invasive diagnosis and assessment of brain injury. The early identification and longitudinal assessment of neuronal damage in subjects suffering from or at risk of suffering from a TBI (e.g., football players, boxers, military personnel, fall victims) will improve clinical outcomes by guiding critical medical and behavioral decision making. | 12-03-2015 |
20150352181 | METHODS FOR TREATING TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA WITH APOLIPOPROTEIN D - The invention provides methods for treating tissue damage associated with impaired blood flow using ApoD, or an active variant thereof, or an agent that increases the expression of ApoD. The invention also encompasses active variants of ApoD for use in the methods. | 12-10-2015 |
20150353902 | Use of Human Biliverdin Reductase and Fragments Thereof for the Treatment of Protein Kinase C-Delta and ERK Related Conditions - The present invention is directed to methods of modulating PKC-δ activity and PKC-δ/ERK complex activity in cells via biliverdin reductase. Methods and compositions for diagnosing and treating a PKC-δ and PKC-δ/ERK complex related condition are also disclosed. | 12-10-2015 |
20160008395 | Process For The Preparation Of A Non-Corrosive Base Solution And Methods Of Using Same | 01-14-2016 |
20160022749 | METHOD OF IMPROVING HEMATOLOGICAL PARAMETERS AND BRAIN DYSFUNCTION WITH GANODERMA TSUGAE EXTRACT - The invention relates to a method of improving hematological parameters and brain dysfunction by administrating an extract of | 01-28-2016 |
20160022771 | SENSATION-IMPROVING AGENT - An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics. | 01-28-2016 |
20160025745 | METHODS OF DIAGNOSING AND TREATING FIBROSIS - The present invention is directed to methods of diagnosing and treating a fibrotic condition in a mammalian subject. These methods involve measuring the levels of trimethylation at lysine residue 27 of histone-3 and/or measuring the expression levels of EZH2 or YY-1. Agents useful for treating fibrosis or a fibrotic condition are also disclosed. | 01-28-2016 |
20160044949 | PROTEIN COMPOSITION AND PRODUCTION PROCESS THEREFOR - The present invention provides a protein composition comprising a milk basic protein fraction; and at least one stabilizer selected from the group consisting of soybean polysaccharides, xanthan gum, pectin, gum arabic, gum ghatti, carrageenan, locust bean gum, sodium caseinate, lecithin, and carboxymethylcellulose. The protein composition significantly improves the heat resistance of the milk basic protein fraction. The present invention achieves heat treatment of a protein composition and food, beverage, feed, and pharmaceutical comprising such a protein composition at a temperature exceeding 90° C. without deactivation of the milk basic protein fraction. | 02-18-2016 |
20160051636 | Animal Feed Enzymes - The present invention relates to methods of controlling the growth of microorganisms in animals and animal feed. In particular, the present invention relates to a method of controlling the growth of microorganisms in animals with an antimicrobial composition, the treatment of animal feed with an antimicrobial additive and antimicrobial compositions. | 02-25-2016 |
20160075745 | MITOCHONDRIAL PROTEINS CONSTRUCTS AND USES THEREOF - Disclosed are novel fusion protein constructs comprising a functional mitochondrial protein, that can enter mitochondria within intact cells. Further disclosed are methods of treating mitochondrial disorders by the disclosed fusion proteins and compositions therefor. | 03-17-2016 |
20160089422 | METHOD FOR INACTIVATING A PRION PROTEIN - The invention relates to a process for inactivating pathological prion proteins (PrPsc) in a sample or a material which may be contaminated by a pathological prion protein, wherein the sample or the material which may be contaminated by a pathological prion protein is put into contact with at least one methionine sulfoxide reductase. | 03-31-2016 |
20160101034 | ENZYMATIC SYSTEM-CONTAINING COSMETIC COMPOSITIONS - Cosmetic or pharmaceutical compositions are disclosed herein for application to skin, hair and/or a nail of a subject, as well as methods utilizing same for administering hydrogen peroxide to skin, hair and/or a nail, and kits for applying same. The compositions comprise a hydrogen peroxide-producing enzyme, and a substrate of the hydrogen peroxide-producing enzyme. Further disclosed herein are cosmetic compositions and kits for lightening skin and/or hair, which further comprise a lignin peroxidase, as well as cosmetic methods utilizing same. | 04-14-2016 |
20160106816 | TOPICAL THERAPEUTIC FORMULATIONS - The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites. | 04-21-2016 |
20160129039 | Process For The Preparation Of A Non-Corrosive Base Solution And Methods Of Using Same - The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, Lesch-Nyhan syndrome, hemochromatosis, Alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, Parkinson's, Reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, Hepatitis C, methicillin-resistant | 05-12-2016 |
20160137701 | SECRETAGOGUES DERIVED FROM OXALOBACTER FORMIGENES - The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue. | 05-19-2016 |
20160175405 | FUSION PROTEINS AND METHODS FOR TREATING HIV INFECTION AND AIDS RELATED SYMPTOMS | 06-23-2016 |
20160184441 | PROLAMIN-BASED FILM AND METHOD FOR MANUFACTURING PROLAMIN-BASED ORAL FILM FOR PROTECTING ACTIVITY OF ANTI-OXIDATIVE MATERIAL - Exemplary embodiments relate to a oral film including an anti-oxidative material having a high level of activity and a method for manufacturing the oral film for protecting the activity of an anti-oxidative material. The activity of the anti-oxidative material is retained under harsh conditions. An exemplary embodiment includes manufacturing a prolamin-based film for oral delivery. The method includes preparing a solution containing prolamin, glycerol formal, an anti-oxidative material, and a solvent including alcohol, and evaporating the solvent under a reduced pressure condition at a temperature of 0° C. to 80° C. An exemplary embodiment also includes a film for oral delivery, prepared by the preceding method, the film includes an anti-oxidative material that maintains activity at a high level. An exemplary embodiment also includes a film for oral delivery, prepared by the immediately preceding method, the film including prolamin, glycerol formal, and an anti-oxidative material having a high level of activity. | 06-30-2016 |
20160193303 | LEVERAGING OXIDATIVE STRESS PATHWAYS IN LACTIC ACID BACTERIA TO PROMOTE GUT HOMEOSTASIS | 07-07-2016 |
20160199407 | HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION | 07-14-2016 |
20180023217 | ANTIMICROBIAL FIBERS AND COMPOSITIONS | 01-25-2018 |